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ABSTRACT 
Background: Hypoxic-ischemic encephalopathy (HIE) accounts for the majority of 
developmental, motor and cognitive deﬁcits in children, leading to life-long 
neurological impairments. Since (1) transient brain ischemia followed by 
reoxygenation alters ionic homeostasis in adult brain and the plasma membrane 
sodium/calcium exchanger (NCX) plays a fundamental role in the maintenance of 
ionic homeostasis during brain ischemia, we aim to demonstrate the involvement of 
NCX in the pathophysiology of HIE. 
Methods: Experimental HIE was induced in postnatal day 7 (P7) mice by unilateral 
elettrocoagulation of the right common carotid artery and subsequent 60 minutes 
exposure of animals to 8% O2. Expression profiles of NCX from embryos stage to 
adulthood was done using HI and naïve hippocampus mice. To assess the effect of 
NCX pharmacological activation, brain infarct volume was evaluated in propidium 
iodide stained hippocampus sections, obtained at several time points after the 
administration of the newly synthesized NCX activator, Neurounina. Moreover, the 
effect of NCX activation on learning and memory was evaluated in P60 mice. 
Results: An age-dependent NCX-1 and NCX-3 increased expression was evidenced 
in immature hippocampus in wild-type untreated animals. By contrast NCX-1 and 
NCX-3 expression was significantly reduced starting from 7 days until 60 days after 
the hypoxic-ischemic insult. NCX-2 expression did not show any change in the naïve 
and HI mice at all considered time intervals. Notably, NCX pharmacological activation 
by the newly synthesized compound neurounina not only reduced infarct volume but 
improved also the spatial and object memory 8 weeks after HI induction in P7 mice. 
These findings suggest that an altered ionic homeostasis mediated by the reduced 
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expression of NCX contributes to long-term cognitive deficits in neonatal mice 
exposed to HIE.  
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1. PREMISE 
In 1861, William John Little reported on a series of 68 cases of difficult birth, which he 
related to later developments of neurological deficits, such as spastic diparesis (a 
movement disorder that primarily affects the lower limbs). This condition, originally 
known as Little’s disease, became generally known as spasticity or cerebral palsy 
(CP) (Little, 1861). CP denotes a condition of the brain reflected by movement 
limitation that is often associated with some degree of cognitive impairment. It is now 
known that in utero hypoxic-ischemic (HI) events (e.g. placental insufficiency, chronic 
fetal-to-maternal hemorrhage, stroke, infection and inflammation), perinatal events 
(e.g. placental abruption, respiratory failure) and neonatal disorders (e.g. chronic lung 
disease) are associated with acquired brain injuries that lead to CP (Silbereis et al, 
2010). 
The timing of the vascular event leading to hypoxia-ischemia suggested the 
classification based on the gestational or postnatal age at diagnosis. The suggested 
subcategories are (1) fetal hypoxia ischemia, diagnosed before birth by using fetal 
imaging methods or in stillbirths on the basis of neuropathologic examination, (2) 
neonatal hypoxia ischemia, diagnosed after birth and on or before the 28th postnatal 
day (including in preterm infants), and (3) presumed perinatal hypoxia ischemia, 
diagnosed in infants >28 days of age in whom it is presumed (but not certain) that the 
ischemic event occurred sometime between the 20th week of fetal life through the 
28th postnatal day. 
The term hypoxia (anoxia) denotes a partial (or total) oxygen deficiency in one or 
more tissues of the body including blood (hypoxemia, anoxemia) and it is a direct 
consequence of asphyxia. The term asphyxia indicates the condition in which lung or 
placenta gas exchange are altered, leading to a progressive hypoxemia and 
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hypercapnia with subsequently bradycardia and hypotension. The moderate-severe 
hypoxia is followed by metabolic acidosis due to accumulation of lactic acid resulting 
from anaerobic metabolism, instead asphyxia is generally associated with metabolic 
and breathing acidosis. Ischemia originates from the reduction or blockade of blood 
flow resulting in hypotension or vessel occlusion. In the fetus or newborn the 
ischemia is determined by previous hypoxia-acidosis with depressing effect on the 
cardiovascular system or by vascular occlusion. Normally in this clinical picture 
hypoxia and cerebral ischemia occur in the same time and this is the reason why it is 
often defined as hypoxic-ischemic injury (HII). 
The hypoxic-ischemic encephalopathy (HIE) is the most important consequence of 
perinatal asphyxiation and is one of the major cause of neonatal death and 
neurological disability in children. The estimated incidence is approximately 1-6/1000 
in newborns and up to 60% in premature infants (Ferriero, 2004). Half of children with 
this serious disease presents a clinical neuromotor seriously compromised picture 
with tetraplegia and spastic paraplegia, the other half shows a variety of neurological 
problems, such as epilepsy and / or slow in learning and memory capability. The 
precise reasons why birth injuries, including hypoxic ischemic encephalopathy, 
happen are not entirely known. There is a great deal of debate in the medical 
community on the exact cause of this particular condition and on the possibility to 
prevent and detect it before injury occurs to the newborn. Some research data has 
found that maternal hypotension, umbilical cord complications, abruption placentae, 
maternal uterine rupture, and other assorted complications can result in hypoxic 
ischemic encephalopathy. Sometimes, neonatal brain injury is recognized because it 
evolves from lethargy to hyper-excitability to stupor during the first three days of life, 
but it often eludes diagnosis, especially in premature infants with very low birth 
weight, because obvious signs are lacking or because signs that are present are 
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attributed to developmental immaturity. Sarnat in 1976 developed the most common 
scoring scale (Fig.1) (Sarnat & Sarnat, 1976) to distinguish mild, moderate and 
severe hypoxic ischemic encephalopathy according to the symptoms. Clinically 
subtle signs and symptoms lead to a delay in the diagnosis of cerebral palsy, 
learning disabilities, and complex behavioral disorders until later in childhood.  
The outcomes of HIE are devastating and permanent, making it a major burden for 
the patient, the family, and society. In addition, there are currently no available 
treatments for this condition, and the management of infants with hypoxic/ischemic 
injury provides mainly primary resuscitation measures. In fact, despite the 
experimental studies in recent years have contributed to shed light on the complex 
pathogenesis on which newborn brain damage lays on, strategies for clinical 
diagnosis and therapeutic intervention are still insufficient. 
Therefore, it is critical to identify and develop new therapeutic strategies to alleviate 
the burden of this disease. However, the lack of available treatment mirrors the 
paucity in the knowledge of the mechanisms on which this pathology lays on. In fact, 
the underlying pathophysiology of HIE is not completely known and is difficult to 
investigate mainly because of the difficulties to recruit comparable HI human 
newborns and therefore to conduct an appropriate clinical trial. Therefore, neonatal 
rodents model of HI brain injury have been developed in order to mimic human 
condition.  
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Fig. 1. Sarnat scoring scale. The clinical characteristics of HIE can be described as mild stage1, 
moderate stage2, or severe stage 3 (Sarnat & Sarnat, 1976).  
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2. INTRODUCTION 
2.1 NEONATAL HYPOXIA ISCHEMIA PATHOPHYSIOLOGY 
Brain hypoxia and ischemia due to systemic hypoxemia, reduced cerebral blood flow 
(CBF), or both are the primary physiological processes that lead to hypoxic-ischemic 
encephalopathy (Ferriero, 2004; Grow & Barks, 2002; Perlman, 2004). The initial 
compensatory adjustment to an asphyxial event is an increase in CBF due to hypoxia 
and hypercapnia. This is accompanied by a redistribution of cardiac output to 
essential organs, including the brain, heart, and adrenal glands. A blood pressure 
(BP) increase due to increased release of epinephrine further enhances this 
compensatory response.  
In adults, CBF is maintained at a constant level despite a wide range in systemic BP. 
This phenomenon is known as the cerebral autoregulation, which helps maintain 
cerebral perfusion. The physiological aspects of CBF autoregulation has been well 
studied in perinatal and adult experimental animals. In human adults, the BP range at 
which CBF is maintained is 60-100 mm Hg. 
Limited data in the human fetus and the newborn infant suggest that CBF is stable 
over much narrower range of BPs (Papile et al, 1985; Rosenkrantz et al, 1988). 
Some experts have postulated that, in the healthy term newborn, the BP range at 
which the CBF autoregulation is maintained may be only between 10-20 mm Hg 
(compared with the 40 mm Hg range in adults noted above). In addition, the 
autoregulatory zone may also be set at a lower level, about the midpoint of the 
normal BP range for the fetus and newborn. However, the precise upper and lower 
limits of the BP values above and below which the CBF autoregulation is lost remain 
unknown for the human newborn. 
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In the fetus and newborn suffering from acute asphyxia, after the early compensatory 
adjustments fail, the CBF can become pressure-passive, at which time brain 
perfusion depends on systemic BP. As BP falls, CBF falls below critical levels, and 
the brain injury secondary to diminished blood supply and a lack of sufficient oxygen 
occurs. This leads to intracellular energy failure. During the early phases of brain 
injury, brain temperature drops, and local release of neurotransmitters, such as 
gamma-aminobutyric acid transaminase (GABA), increase. These changes reduce 
cerebral oxygen demand, transiently minimizing the impact of asphyxia. 
The immature brain may be more vulnerable to oxidative damage than the adult brain 
due to high concentration of unsaturated fatty acids and the availability of redox-
active iron in the developing brain (Lafemina et al, 2006). Moreover, the anatomo-
pathological lesions and the consequential long term outcomes are different in the 
term compared to preterm newborn. In the first group, the cerebral gray matter 
involvement (cerebral cortex, hippocampus, basal ganglia, cerebellar hemispheres) 
is predominant, in the second group, white matter injury is more frequent. There are 
many factors that determine the different topography of perinatal hypoxic-ischemic 
brain damage: cellular or regional intrinsic vulnerability, vascular factors, nature and 
timing of the insult, age and maturity of the newborn, contingent factors such as 
hypoglycemia, sepsis or malnutrition. Since it’s very hard to conduct a clinical trial 
with neonates and also really tough to make a proper diagnosis we can understand 
why the underlying mechanisms of neonatal HIE remain unclear. Today we know 
thanks to animal model of HI that neonatal brain injury evolves over days or weeks 
so different kind of treatment can be attempted as the injury evolves. (Fig. 2) 
(Ferriero, 2004). 
At the cellular level, neuronal injury in hypoxic-ischemic encephalopathy is an 
evolving process. The magnitude of the final neuronal damage depends on duration 
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and severity of the initial insult combined to the effects of reperfusion injury, and 
apoptosis. At the biochemical level, a large cascade of events follow hypoxic-
ischemic encephalopathy injury.  
In the next paragraphs we will examine the main pathophysiological mechanisms 
involved in cell death after HIE. 
 
Fig. 2. Mechanisms of Brain Injury in the Term Neonate. Oxidative stress and excitotoxicity, through 
downstream intracellular signaling, produce both inflammation and repair. Cell death begins 
immediately and continues during a period of days to weeks. The cell-death phenotype changes from 
an early necrotic morphology to a pathology resembling apoptosis. This evolution is called the 
necrosis– apoptosis continuum. (Ferriero, 2004) 
 
2.1.1 MECHANISM OF CELL DEATH: EXCITOTOXICITY 
Current research shows the importance of glutamate mediated excitotoxicity 
following neonatal HI. Glutamate is the main excitatory neurotransmitter in the central 
nervous system and acts through two broad classes of receptors: ion channel linked 
ionotropic receptors and metabotropic receptors (mGluR), which are coupled with G-
proteins inducing intracellular messenger cascades (Palmada & Centelles, 1998) 
(Tanabe et al, 1992). Four main subtypes of glutamate-gated channels have been 
characterized pharmacologically and they have been named according to their 
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preferred agonist, N-methyl-D-aspartate (NMDA), high affinity kainate (KA), α-amino-
3-hydroxy-5- methyl-4-isoxazole propionate (AMPA) and 2-amino-4- Mechanisms 
Underlying Neonatal Hypoxia Ischemia The Open Drug Discovery Journal, 2010, 
Volume 2 131 phosphobutyrate (AP4)(Palmada & Centelles, 1998). 
A prolonged hypoxia or HI results in depletion of cellular energy stores (ATP), 
depolarization of neurons and glia and release of excitatory amino acids into the 
extracellular space, particularly the glutamate. The excessive release of glutamate 
and/or impaired uptake by glia may result in overactivation of NMDA and AMPA 
receptors that cause an increase in Ca2+ influx which activates proteases and 
endonucleases, such as calpains, resulting in the breakage of cytoskeletal and 
nuclear structure and DNA damage. On the other hand, the influx of Na+ ions via 
AMPAR causes cell swelling and depolarization. These are the major cell death 
mechanisms in response to excitotoxicity that eventually results in necrosis or 
apoptosis. 
A large amount of work has been accumulated showing that glutamate extracellular 
concentrations briskly rise during acute brain injury, thus triggering an influx of Ca2+ 
and Na+ ions into neurons through ionotropic glutamate receptor subtypes. This 
evidence has led to the elaboration of the paradigm of glutamate excitotoxicity that 
explains ischemic neuronal cell death as a mere consequence of Na+ and Ca2+ influx 
through glutamate receptors (Olney & Sharpe, 1969). Although this theory has been 
guiding basic research in the field of neurodegeneration for almost three decades, 
more recently it has become the object of serious criticism and reassessment. What 
has aroused such skepticism among researchers has been the fact that although 
first, second, and third generation glutamate receptor antagonists have long yielded 
promising results in animal models of brain ischemia, they have failed to elicit a 
neuroprotective action in adult stroke and in HI newborns. Therefore, the theory of 
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excitotoxicity can only explain some of the events occurring in the acute phase of 
anoxic insult but cannot be seen as a major target for developing new therapeutic 
avenues for brain ischemia. In the last decade, several seminal experimental works 
are markedly changing the scenario of research of principal actors of an ischemic 
event. In fact, it has been shown that some integral plasma-membrane proteins, 
involved in the control of Ca2+, Na+, K+, H+ ions influx or efflux and, therefore, 
responsible for maintaining the homeostasis of these four cations, might function as 
crucial players in the brain ischemic process. Indeed, these proteins, by regulating 
Ca2+, Na+, K+, H+ homeostasis, may provide the molecular basis underlying 
glutamate independent Ca2+ overload mechanisms in neuronal ischemic cell death 
and, most importantly, may represent more suitable molecular targets for therapeutic 
intervention (Annunziato et al, 2004). 
 
2.1.2 OTHER NON-NMDA DEPENDENT PATHWAYS 
Non NMDA-dependent mechanisms can disrupt ionic homeostasis in neonatal brains 
after HI and contribute to brain damage. This includes Na+/H+ exchanger (NHE)  and 
nonselective Ca2+-activated ATP-sensitive cation channel. Indeed, HI leads to a 
decrease in the intracellular pH (pHi). To counteract the subsequent acidosis, the 
Na+/H+ exchanger and H+ pump in the plasma membrane are activated to remove 
the excess in H+ ions. NHE isoform 1 is the most ubiquitously expressed isoform in 
the CNS (Luo & Sun, 2007) (Ma & Haddad, 1997). NHE-1 becomes overstimulated 
following ischemia-induced intracellular acidosis (Avkiran, 2001) and by extracellular 
regulatory kinase-mediated phosphorylation (Luo & Sun, 2007; Malo et al, 2007). 
NHE1-mediated ischemic and reperfusion damage largely result from an increase in 
intracellular Na+, which promotes Ca2+ influx by reverse mode operation of the Na+ ⁄ 
Ca2+ exchanger NCX (Kintner et al, 2007; Lee et al, 2005). Non NMDA-dependent 
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mechanisms could also support ionic homeostasis in neonatal brains after HI and 
reduce brain damage. Na+ ⁄ Ca2+ exchanger NCX can facilitate both Ca2+ and Na+ 
flow in a bidirectional way through the plasma membrane (Blaustein & Lederer, 1999; 
Philipson & Nicoll, 2000) with a stoichiometry of 3 Na+ ions versus 1 Ca2+ ion. 
Depending on the intracellular levels of Na+ and Ca2+, NCX can operate in the 
forward mode by extruding one Ca2+ against three entering Na+, using the Na+ 
gradient across the plasma membrane as a source of energy (Annunziato et al, 
2004; Blaustein & Lederer, 1999). Alternatively, in the reverse mode, NCX can 
function as Na+ efflux–Ca2+ influx. Because of its high exchange capacity, NCX is 
well-suited for rapid recovery from high intracellular Ca2+ concentrations ([Ca2+]i) and 
may play an important role in maintaining Ca2+ homeostasis and protecting cells from 
Ca2+ overload and eventual death (Annunziato et al, 2004; Blaustein & Lederer, 
1999). 
 
2.1.3 OXIDATIVE STRESS 
The neonatal brain, with its high concentrations of unsaturated fatty acids, high rate 
of oxygen consumption, low concentrations of antioxidants, and availability of redox-
active iron is particularly vulnerable to oxidative damage (Tan et al, 1996). In the very 
immature brain, oligodendrocyte progenitor cells and preoligodendrocytes are 
selectively vulnerable to the depletion of antioxidants or exposure to exogenous free 
radicals (Sheldon et al, 1998). Mature oligodendrocytes, in contrast, are highly 
resistant to oxidative stress, owing in part to differences in the levels of expression of 
antioxidant enzymes and proteins involved in programmed cell death. These 
characteristics of oligodendrocytes may explain why white matter often is injured 
selectively in the brain of the premature newborn. 
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2.1.4 INFLAMMATION 
Inflammatory mediators also play an important role in the pathogenesis of HI in 
immature brains (Hedtjarn et al, 2004). This inflammation could result from maternal 
infection which is a well known risk factor for the white matter disease in the 
newborns and leads to neuronal damage and cell loss (Dammann et al, 2002). 
Inflammation after HI has both beneficial and detrimental effects. Inflammatory 
cytokines may have a direct toxic effect via increased production of iNOS, 
cyclooxygenase and free radical release (Perlman, 2007). Expression of interleukin-
1-β and tumor necrosis factor α (TNF-α) mRNA has been detected in the area of 
infarction within 1-4 h after HI (Hagberg et al, 1996). Thus, inflammation may 
represent a common pathway of brain injury. The beneficial effects of inflammatory 
cytokines come from their neurotrophic effects. TNF-α knockout mice have increased 
neuronal cell damage with increased oxidative stress after ischemia, suggesting an 
important role for TNF- α in neuroprotection. Injury-induced microglial activation was 
also suppressed in TNF- α knockout (Bruce et al, 1996). 
 
2.1.5 NECROSIS AND APOPTOSIS 
Both necrotic and apoptotic cell death occurs following neonatal HI. Necrotic cells 
show early rupture of the plasma membrane, swelling of intracellular organelles, 
shrinkage of cell volume and inflammation response activation resulting from the 
spilled cytosolic contents (Edinger & Thompson, 2004). In contrast, programmed cell 
death, or apoptosis, is the mechanism for refining cell connections and pathways 
during brain development. Recent data suggest that apoptosis plays a prominent role 
in the evolution of hypoxic–ischemic injury in the neonatal brain and may be more 
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important than necrosis after injury (Hu et al, 2000). During neonatal brain injury, 
excitotoxicity, oxidative stress, and inflammation all contribute to the cell death by 
apoptosis or necrosis, depending on the region of the brain affected and the severity 
of the insult. Signals from cytokine death receptors, for example, result in nitric 
oxide–mediated necrosis when endogenous inhibitors of apoptosis are abundant 
(Raoul et al, 2002) and in apoptosis when the inhibitors are deficient. 38 These 
death-receptor proteins have been documented in the brain and the cerebrospinal 
fluid of newborns after brain injury, (Felderhoff-Mueser et al, 2003; van Landeghem 
et al, 2002) suggesting that this pathway may be a potential therapeutic target. 
 
2.2 CLINICAL THERAPIES 
It is very difficult to predict during the neonatal period which neonates will suffer the 
most profound damage after an insult to the central nervous system, since more than 
30 percent of neonates presenting with moderate encephalopathy have normal 
outcomes. 
 
2.2.1 BARBITURATES 
The first class of drugs used in HIE infants were barbiturates. This GABAergic 
agonists  show variable success in clinical trials after HI in neonates. Indeed, when 
thiopental was used in 32 asphyxiated neonates no significant difference was found 
in the frequency of seizures between control and treated group and it did not appear 
to have a cerebral sparing effect (Goldberg et al, 1986). Thiopental was begun at a 
mean age of 2.3 hours and was given as a constant infusion that delivered 30 mg/kg 
over 2 hours. Treatment was continued at a lower dose for 24 hours. Interestingly, 
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phenobarbital when given 20 mg/kg intravenously to neonates with HI within 6 hours 
of life, significantly decreased the incidence of seizures (Singh et al, 2005). Three-
year long term follow up of the newborns with HI after 40 mg/kg of phenobarbital 
therapy revealed better neurological outcome (Hall et al, 1998),(Shalak & Perlman, 
2004). The role of barbiturates in the severely injured population remains unclear 
(Shalak & Perlman, 2004) . 
 
2.2.2 ALLOPURINOL 
Free radicals such as hydroperoxide (H2O2), hydroxyl radical (OH), superoxide 
radical (O2 −), and peroxynitrite (ONOO–) play a significant role in the development 
of damage after HI. The primary source of superoxide in reperfused reoxygenated 
tissues appears to be the enzyme xanthine oxidase, released during ischemia by a 
calcium triggered proteolytic attack on xanthine dehydrogenase. Allopurinol is a 
xantine-oxidase inhibitor; in high concentrations allopurinol also scavenges hydroxyl 
radicals and prevents free radical formation by chelating their catalyst non-protein 
bound iron. High doses are needed for neuroprotection. Studies in immature rats 
found that allopurinol treatment 15 min after cerebral hypoxia–ischaemia reduced 
brain edema and long term brain damage. In this study, the rat pups received either 
allopurinol (135 mg/kg subcutaneously) or saline. A Cochrane review in 2008 
(Chaudhari & McGuire, 2008) suggested that the available data are not sufficient to 
determine whether allopurinol has clinically important benefits for newborn infants 
with hypoxic–ischaemic encephalopathy. The review suggested that larger trials are 
needed which should assess allopurinol as an adjunct to therapeutic hypothermia in 
infants with moderate and severe encephalopathy and should be designed to 
exclude clinically important effects on mortality and adverse long-term 
neurodevelopmental outcomes. Three trials were included in the meta-analysis of 
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allopurinol for preventing mortality and morbidity in newborn infants with suspected 
hypoxic–ischemic encephalopathy (Benders et al, 2006; Gunes et al, 2007; Van Bel 
et al, 1998). Meta-analysis did not reveal a statistically significant difference in the 
risk of death during infancy or incidence of neonatal seizures. Only one trial 
assessed neurodevelopment in surviving children and did not find a statistically 
significant effect. As allopurinol acts through its free radical scavenger property it 
must be administered early, even during delivery; fortunately allopurinol crosses the 
placenta. In 2009, the Dutch group demonstrated that maternal allopurinol (500 mg) 
during fetal hypoxia lowers cord blood levels of S-100B in pregnancies in which fetal 
hypoxia was suspected at N36 weeks gestation (Torrance et al, 2009); fetal hypoxia 
was indicated by abnormal/non-reassuring fetal heart rate tracing or fetal scalp pH of 
b7.20. Following on from this the ALLO-trial has started in the Netherlands 
(Kaandorp et al, 2010); the proposed trial is a randomized double blind placebo 
controlled multicenter study in pregnant women at term in whom the fetus is 
suspected of intra-uterine hypoxia. Allopurinol 500 mg IV or placebo will be 
administered antenatally to the pregnant woman when fetal hypoxia is suspected.  
 
2.2.3. ERYTHROPOIETIN 
Erythropoietin is a glycoprotein hormone that controls erythropoiesis (Patti et al) . 
Erythropoietin is a cytokine for erythrocyte precursors in the bone marrow and is 
produced by the peritubular capillary endothelial cells in the kidney. The safety of 
recombinant human Epo (rEPO) has been demonstrated in clinical studies for the 
prevention and treatment of anaemia of prematurity (Ohls et al, 2004). Epo is up-
regulated in umbilical cord blood from babies who have suffered perinatal asphyxia 
(Ruth et al, 1990), which may be an endogenous repair mechanism. Several pre-
clinical studies have suggested a neuroprotective effect of Epo following hypoxia–
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ischaemia and reperfusion (Maiese et al, 2005). Iin neonatal models systemically 
administered Epo is neuroprotective (Kellert et al, 2007) with early and high dose 
treatment required to reduce brain injury (5000U/kg), furthermore it promotes 
neurogenesis (Gonzalez et al, 2007). There is also data suggesting that multiple 
doses of Epo are required for sustained neuroprotection and reduced tissue loss 
(Gonzalez et al, 2009). Epo is shown to have neuroprotective effects through 
different mechanisms such as direct neurotrophic effect, decreased susceptibility to 
glutamate toxicity, induction of anti-apoptotic factors, decreased inflammation, 
decreased nitric oxide-mediated injury, 
direct antioxidant effects, and protective effects on glia. Interestingly, the 
antioxidative effect of Epo may be enhanced by the increased erythropoesis 
utilizating the free-iron which has accumulated following hypoxia–ischaemia (Palmer 
et al, 1999). The dosage for neuroprotection (1000–30,000 U/kg) is above the range 
used in anaemia; Epo is a relatively large molecule (30.4 kDa) to cross the blood 
brain barrier. However following high-dose rEpo administration in non-human 
primates and sheep, neuroprotective concentrations of Epo was found in the CSF by 
2–2.5 h after injection (Juul et al, 2004). High Epo dose was well tolerated in these 
studies . Pre-clinical studies of the interaction of Epo with hypothermic 
neuroprotection are required before progression to clinical trials of combined therapy. 
Interestingly, other neuroprotective agents up-regulate endogenous erythropoietin; 
for example, xenon up-regulates erythropoietin expression (Ma et al, 2009) and 
easily crosses the blood brain barrier providing an alternative mechanism to harness 
erythropoietin protection in the CNS. 
Whether higher doses of Epo can improve outcomes without inducing complications 
is unknown. Concerns over the use of high doses of erythropoietin include possible 
thrombotic and hematological complications and real safety concerns have arisen in 
 
 
21 
 
2 recent adult studies. In a pilot study of out-of-hospital cardiac arrest, patients 
treated with hypothermia and early high dose Epo (40 000 IU as soon as possible 
after resuscitation and every 12 h for the first 48 h were compared with case-
matched controls who received therapeutic hypothermia alone (Cariou et al, 2008). A 
higher survival rate with none or minimal cerebral sequelae were seen in the Epo 
treated patients but adverse effects related to vascular thrombosis occurred (Cariou 
et al, 2008). In another study of adult stroke patients, a higher death and 
complication rate was observed in those receiving Epo compared with placebo; 
complications included intracerebral hemorrhage, brain oedema and thrombotic 
events (Ehrenreich et al, 2009). 
 
2.2.4. ANTICONVULSANTS 
Data from both animal and human studies suggest that seizures amplify neonatal 
hypoxic–ischemic brain damage (Glass et al, 2009; Wirrell et al, 2001). In a recent 
study of newborns with HIE with MRS used to assess tissue metabolic integrity, the 
severity of seizures was independently associated with brain injury (Calabresi et al, 
2003; Miller et al, 2002). These results provide some support for the hypothesis that 
effective prevention of neonatal seizures could attenuate brain injury. Anticonvulsant 
drugs (AEDs) are being studied as possible neuroprotective agents on the basis of 
the similar cascade of cellular events triggered by seizures and acute hypoxia–
ischaemia. Two drugs of particular interest in perinatal asphyxia are topiramate and 
levetiracetam. opiramate is an AED drug used safely in children (Kim et al, 2009). 
Topiramate has actions on many cell pathways: it acts through modulation of 
alphaamino- 3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate and gamma-
aminobutyric acid (GABA)A-activated ion channels and voltage-activated Na+ and 
Ca++ channels, which may reduce excessive glutamate release after hypoxia-
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ischaemia (Herrero et al, 2002; Taverna et al, 1999; Zona et al, 1997). Topiramate 
suppresses the pre-synaptic voltage-sensitive sodium channel of excitatory synapses 
and enhances GABA-mediated chloride flux and GABA-evoked chloride currents in 
murine brain neurons and increases seizure threshold(White et al, 1997). In a 
neonatal rat stroke model, neither topiramate nor hypothermia alone conferred 
protection, whereas combined treatment with topiramate and hypothermia improved 
functional performance and reduced severity of brain injury compared with delayed 
hypothermia alone (O'Brien et al, 2006). Other studies have shown that topiramate 
on its own is neuroprotective in neonatal rat pups although the post-treatment 
window appears to be relatively narrow (2 h) (Noh et al, 2006). In another p7 rodent 
model post-insult topiramate was protective against hypoxic– ischemic white matter 
injury and decreased subsequent neuromotor deficits (Follett et al, 2004). In this 
study topiramate attenuated AMPA-kainate receptor-mediated cell death and calcium 
influx, as well as kainateevoked currents in developing oligodendrocytes, similar to 
the AMPA– kainate receptor antagonist 6-nitro-7-sulfamoylbenzo-(f)quinoxaline- 2,3-
dione (NBQX). Notably, protective doses of NBQX and topiramate did not affect 
normal maturation and proliferation of oligodendrocytes (Follett et al, 2004). 
Topiramate was shown to protect against white matter injury in a newborn piglet 
model when given as infusion 1 h after hypoxia– ischaemia followed by maintenance 
doses for 3 days(Schubert et al, 2005). Interestingly, topiramate administration did 
not affect seizure frequency. Two dose regimens were used: a low dose (loading 
dose of 20 mg/kg and a maintenance dose of 10 mg/kg/day) or a higher dose 
(loading dose of 50 mg/kg followed by 20 mg/kg/day). Topiramate reduced cell loss 
in a dose dependent way, however there was concern that increased apoptosis was 
seen in the white matter of high dose treated animals. Topiramate is an attractive 
agent to consider for clinical trials, however pre-clinical studies are needed to assess 
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the effect of topiramate on neurodegeneration. One study has suggested that 
although Topiramate and Levetiracetam alone did not induce cell death in 8 day old 
rat pups, when both drugs were given in combination with phenytoin, then cell death 
was increased (Kim et al, 2007a). In addition further study on the effect of 
hypothermia on the metabolism of Topiramte is needed as some studies have shown 
a reduction in both absorption and elimination of topiramate with therapeutic 
hypothermia (Filippi et al, 2009). Levetiracetam was approved by the US FDA in 
1999; in the last 10 years it has become one of the first-line AEDs and has been 
evaluated in small uncontrolled studies and case series as an off-label treatment for 
status epilepticus, for nonepileptic neurological conditions and for some psychiatric 
conditions. Levetiracetam has not been approved for any indication other than 
chronic epilepsy. In a recent small pilot study of the treatment of neonatal seizures 
with levetiracetam, there were no adverse effects and all six patients treated with oral 
levetiracetam became seizure free within 6 days (Furwentsches et al, 2010). In 
addition to its efficacy in seizure treatment, some studies suggest that levetiracetam 
is neuroprotective (Mazarati et al, 2004). Levetiracetam was administered by 
intraperitoneal bolus injections of 5.5, 11, 22 and 44 mg/kg 30 min before occlusion 
followed by a continuous 24 h infusion of 1.25, 2.6, 5.1 and 10.2 mg/kg per h, 
respectively. Levetiracetam administration reduced the infarct volume by 33% at he 
highest dose tested (Hanon & Klitgaard, 2001). Although there is a lack of clinical 
experience with levetiracetam, this agent is worth investigating further as a 
neuroprotective agent as in contrast to other conventional AEDs such as 
phenobarbitone and phenytoin, it does not induce cell death in the developing brain 
even at high dose (Kim et al, 2007b). 
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2.2.4. HYPOTHERMIA 
Hypothermia is the only standard treatment at present approved for HIE and several 
clinical trials for establishing a better protocol for the use of hypothermia in HI are in 
progress. Therapeutic hypothermia reduces the brain energy use rate and inhibits 
many of the processes involved in primary and secondary energy failure (Laptook, 
2009b). 
The hypothermia neuroprotective mechanisms are not completely understood. 
Possible mechanisms include (1) reduced metabolic rate and energy depletion; (2) 
decreased excitatory transmitter release; (3) reduced alterations in ion flux; (4) 
reduced apoptosis due to hypoxic-ischemic encephalopathy; and (5) reduced 
vascular permeability, edema, and disruptions of blood-brain barrier functions. 
The clinical efficacy of therapeutic hypothermia in neonates with moderate-to-severe 
hypoxic-ischemic encephalopathy has been evaluated in 7 randomized controlled 
trials (Azzopardi et al, 2009; Eicher et al, 2005a; Eicher et al, 2005b; Gluckman et al, 
2005; Jacobs et al, 2011; Shankaran et al, 2005; Simbruner et al, 2010; Zhou et al, 
2010). Inclusion criteria varied slightly. Criteria from the larger trials (NICHD, 
CoolCap, and TOBY) are summarized as follows: 
 
 Near-term infants born at 36 weeks' gestation or more with birth weight of 1800-
2000 g or more, younger than 6 hours at admission 
 Evidence of acute event around the time of birth - Apgar score of 5 or less at 10 
minutes after birth (In the study by Shankaran et al, this needed to be in 
conjunction with either evidence of acute perinatal event or need for assisted 
ventilation for at least 10 min.(Shankaran et al, 2005)), severe acidosis, defined 
as pH level of less than 7 or base deficit of 16 mmol/L or less (cord blood or any 
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blood gas obtained within 1 h of birth), continued need for resuscitation at 10 
minutes after birth 
 Evidence of moderate to severe encephalopathy at birth - Clinically determined 
(at least 2 of the following: lethargy, stupor, or coma; abnormal tone or posture; 
abnormal reflexes [suck, grasp, Moro, gag, stretch reflexes]; decreased or absent 
spontaneous activity; autonomic dysfunction [including bradycardia, abnormal 
pupils, apneas]; and clinical evidence of seizures), moderately or severely 
abnormal amplitude-integrated electroencephalography (aEEG) background or 
seizures (CoolCap and TOBY) 
Therapeutic hypothermia when applied within 6 hours of birth and maintained for 48-
72 hours is a promising therapy for mild-to-moderate cases of hypoxic-ischemic 
encephalopathy (Laptook, 2009a; Shankaran, 2009). Although many components of 
its implementation remain to be optimized, hypothermia therapy is increasingly 
offered to infants with moderate-to-severe hypoxic-ischemic encephalopathy. Some 
even argue that not discussing hypothermia therapy as an option with parents is 
unethical (Perlman & Shah, 2009; Wilkinson, 2009). 
 
2.3 ANIMAL MODELS OF NEONATAL WHITE MATTER INJURY (WMI) 
Due to the difficulties to recruit and conduct clinical trial with newborns several animal 
models have been developed in order to study the mechanism underlying neonatal 
brain injury (Fig. 3) . 
 
2.3.1 RICE AND VANNUCCI MODEL 
The model of neonatal HI was firstly developed by Vannucci and Rice in neonatal 
rats (Rice et al, 1981). The Vannucci/Rice method involves a unilateral carotid artery 
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ligation of postnatal day (P7) rats followed by exposure to 8%oxygen/balanced 
nitrogen at 37°C. The unilateral carotid artery ligation alone does not induce ischemic 
damage due to the intact circle of Willis. Exposure of neonatal rats to 8%oxygen after 
unilateral common carotid ligation results in hypoxemia and hypocapnia produced by 
hyperventilation (Vannucci & Vannucci, 2005). Hypocapnia compensates for the 
metabolic acidosis which is due to lactic acid accumulation secondary to anaerobic 
glycolysis. Therefore, this model causes damage to ipsilateral hippocampus, 
striatum, thalamus and cortex (Welsh et al, 1982).The selection of the age of the 
neonatal rodent and duration of hypoxia vary among researchers. In rats, the 
accepted age has remained at P7, which correlates histologically to a 32 to 34 week 
human neonate (Vannucci & Vannucci, 2005). In mice, the most frequently used age 
is P9, although P7 to P10 are commonly used (Barks et al, 2008; Doverhag et al, 
2008; Stone et al, 2008). Seven to 10 day old mouse brains are similar to a third-
trimester neonatal brains, in terms of cellular proliferation, cortical organization, 
synapse number, neurotransmitter synthetic enzymes and electrophysiology (Liu et 
al, 1999).The time course to induce HI related brain injury varies among different 
animal species and ages. Neonatal rats exposed to hypoxia for over three hours can 
induce brain injury before significant mortality occurs (Vannucci & Vannucci, 2005) . 
Severe forebrain injury was observed following 150 minutes (min) of HI in P7 rats 
(Jiang et al, 2008; Northington et al, 2001). Similarly, time course of HI varies from 15 
min (Jiang et al, 2008) to 2.5 hours (h) in P7 mice (Nakanishi et al, 2009). Thirty min 
of hypoxia can result in moderate injury and 1 h in severe injury in P7 mice (Kendall 
et al, 2006).Necrotic neurodegeneration is seen in the ipsilateral cortex and striatum 
at 3 h post HI (Northington et al, 2001). Apoptotic cell death is detected in the 
thalamus at 24 h post HI (Northington et al, 2001). At 48 h post HI, cells show both 
necrotic and apoptotic appearances in the ipsilateral cortex and striatum in rats 
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(Northington et al, 2001). In mice, damage is only detected in the ipsilateral 
hippocampus at 48 h post HI(Kendall et al, 2006). 
2.3.2 CHRONIC HYPOXIA MODEL 
Infants with chronic lung disease as a complication of premature birth suffer multiple 
hypoxic episodes and are at higher risk of developing CP. Neonatal rodent models 
involving either continuous or intermittent hypoxic rearing have been proposed as 
models of this type of brain injury and display some pathological features of 
developmental WMI (Back et al, 2006; Chahboune et al, 2009; Ment et al, 1998; 
Scafidi et al, 2009). 
  
2.3.3 INTRAUTERINE HYPOXIA ISCHEMIA MODEL 
Intrauterine models of transient global ischemia have been described in the rat and 
rabbit by housing of pregnant dams in hypoxic conditions or by abruption of placental 
blood flow by inflation of a balloon catheter inserted into the uterine artery, 
respectively (Cai et al, 1998; Cai et al, 1995; Hersey et al, 1995). In both rat and 
rabbit, this model recapitulates many histopathological aspects of developmental 
WMI (Derrick et al, 2007). In rabbits, in addition to lesions throughout the cerebral 
gray and white matter, some animals develop spontaneous intraventricular 
hemorrhage with ventriculomegaly and periventricular white matter loss. Detailed 
neurobehavioral assessments have demonstrated that the surviving rabbit kits 
display a wide range of hypertonic motor deficits that resemble CP. This is currently 
the only model that permits such detailed clinico-pathological correlations with 
neurobehavioral outcome and neuro-radiological assessment (Drobyshevsky et al, 
2005). This model has also been used extensively to study the cellular mechanisms 
of WMI. For example, it was recently shown that the susceptibility to WMI during 
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development closely coincided with the timing of appearance of preOLs (Buser et al, 
2010). 
 
2.3.4 GLIOTOXIC INJURY MODEL 
Understanding the repair response after demyelination and oligodendrocyte death 
might be relevant to understanding the failure of myelination during developmental 
insults. In this respect, gliotoxic models, which are traditionally used to study 
demyelinating diseases such as multiple sclerosis (MS), might prove useful for 
understanding developmental WMI. The two main toxin-based models of 
demyelination in adult white matter are (1) systemic administration of cuprizone, 
which induces widespread CNS demyelination, or (2) focal injection of lysolecithin or 
ethidium bromide, which typically induce focal lesions in spinal cord white matter or 
caudal cerebellar peduncle, respectively (Blakemore & Franklin, 2008). Although 
such models lack an inflammatory basis, which might be an important consideration 
in neonatal WMI, they might allow targeted investigation of the responses of 
oligodendrocyte progenitors to WMI and define mechanisms involved in regeneration 
and repair. In addition, they might be useful for assessing mechanisms of myelin 
regeneration that are conserved in both neonatal and adult white matter disorders, 
such as MS. 
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Fig. 3. Overview of common animal models for studying developmental white matter injury 
 
 
 
2.4 SODIUM/CALCIUM EXCHANGER AS POTENTIAL TARGET IN 
BRAIN ISCHEMIA  
 
2.4.1 SODIUM/CALCIUM EXCHANGER 
The Na+/Ca2+ exchanger (NCX) is one of the major membrane proteins involved in 
Ca2+ extrusion at the plasma membrane. The regulation of Ca2+ and Na+ homeostasis 
is a crucial physiological phenomenon in neurons. In fact, Ca2+ ions play a key role as 
a second  messenger in the cytosol and in the nucleus (Choi, 1988), while the Na+ 
ion regulates the cellular osmolarity, inducing action potentials (Lipton, 1999), and it 
is involved in the signal translation (Yu & Choi, 1997). The control of this regulation is 
 
 
30 
 
delegated to ionic channels selective for Ca2+ and Na+, to Na+ pumps, Ca2+ ATP-
dependent and to NCX (Blaustein & Lederer, 1999). The NCX family, which 
exchanges three Na+ ions for one Ca2+ ion or four Na+ ions for one Ca2+ ion 
depending on [Na+]i and [Ca2
+]i (Fujioka et al, 2000; Kang & Hilgemann, 2004; 
Reeves & Hale, 1984) consists of three dominant genes coding for the three different 
isoforms of the exchanger: NCX1 (Nicoll et al, 1990), NCX2 (Li et al, 1994), and 
NCX3 (Nicoll et al, 1996) proteins. These three genes appear to be dispersed, since 
NCX1, NCX2, and NCX3 have been mapped in mouse chromosomes 17, 7, and 12, 
respectively (Nicoll et al, 1996). At the post-transcriptional level, at least 12 NCX1 
and 3 NCX3 proteins are generated through alternative splicing of the primary 
nuclear transcripts. These variants arise from a region of the large intracellular f-loop, 
are encoded by six small exons defined A to F, and are used in different 
combinations in a tissue-specific manner. To maintain an open reading frame, all 
splice variants must include either exon A or B, which are mutually exclusive 
(Quednau et al, 1997). NCX1 is composed of 938 amino acids in the canine heart 
and has a molecular mass of 120 kDa and contains nine transmembrane segments 
(TMS). NCX1 amino terminus (N-terminal) is located in the extracellular space, 
whereas the carboxyl terminus (C-terminal) is located intracellularly. The nine 
transmembrane segments can be divided into an N-terminal hydrophobic domain, 
composed of the first five TMS (1–5), and into a C-terminal hydrophobic domain, 
composed of the last four TMS (6–9). These two hydrophobic domains are important 
for the binding and the transport of ions. The first (1–5) TMS are separated from the 
last four (6–9) TMS through a large hydrophilic intracellular loop of 550 amino acids, 
named the f-loop (Nicoll et al, 1999). Although the f-loop is not implicated in Na+ and 
Ca2+ translocation, it is responsible for the regulation of NCX activity.  
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2.4.2 SODIUM/CALCIUM EXCHANGER ROLE IN ISCHEMIC STROKE 
In an in vivo model of cerebral ischemia, reproduced in our laboratories, based on 
permanent middle cerebral artery occlusion (pMCAO) it has been observed a 
downregulation of about 90% of the levels of expression of NCX1 and NCX3 in 
ischemic core and in the peri-ischemic regions. In other brain districts, belonging to 
the ischemic penumbra, after cerebral ischemia, there was an increase of the levels 
of RNA messenger of NCX3 and NCX1. In contrast, in the same regions, the pMCAO 
causes a decrease in mRNA expression of NCX2. The up-regulation of NCX3 in peri-
infarct tissue has been interpreted as a compensatory mechanism to offset the 
reduced activity of NCX2, that in the course of ischemia is down-regulated and to 
keep at a proper homeostasis ions Na+ and Ca2+.  In essence, the expression of 
NCX1 and NCX3 after permanent middle cerebral artery occlusion (pMCAO) in rats is 
regulated in a differential manner, depending on the region involved in the insult 
(Boscia et al, 2006; Pignataro et al, 2004). Furthermore, antisense-induced 
downregulation of NCX1 and NCX3 or genetic ablation of NCX3 worsens the 
experimentally-induced ischemic damage in mice and rats (Molinaro et al, 2008). 
Evidence for NCX3 neuroprotective role relies in the remarkable broadening ofthe 
infarct volume occurring when NCX3 protein is knocked down with aselective 
antisense oligonucleotide, thereby worsening the neurologic deficits (Pignataro et al, 
2004). Accordingly, it has been recently showed in ischemic NCX3–/– mice 
thatNCX3 exerts a neuroprotective effect (Molinaro et al, 2008). For instance, in 
homozygous ncx3−/− mice subjected to MCAO, an increased brain damage occurs 
(Molinaro et al, 2008). In addition, the silencing of NCX1 and NCX3 expression by 
RNA interference increases cerebellar granule neurons vulnerability to Ca2+ overload 
and excitotoxicity (Bano et al, 2005; Secondo et al, 2007). Moreover, the vulnerability 
to chemical hypoxia of BHK cells overexpressing NCX1 or NCX3 considerably 
 
 
32 
 
increases when either NCX1 or NCX3 is silenced (Bano et al, 2005; Secondo et al, 
2007). Finally, ischemic rats treated with NCX1 or NCX3 antisense display a 
remarkable enlargement of the infarct volume (Pignataro et al, 2004).In a recent 
paper published by Pignataro et al, it has been shown that among the three NCX 
brain isoforms, NCX1 represent a new molecular effector involved in a 
neuroprotective mechanism named “ischemic preconditioning” (Pignataro et al, 2013; 
Pignataro et al, 2011). In effect, the brain possesses internal defense mechanisms 
that can be triggered by several stimuli. Among these mechanisms, preconditioning 
has recently attracted a great deal of interest. Preconditioning  is a phenomenon 
whereby a subliminal injurious stimulus applied before a longer harmful ischemia 
(Dirnagl et al, 2003; Gidday, 2006; Kirino, 2002) is able to exert a remarkable 
neuroprotection, thus establishing a state of tolerance to anoxic conditions. Pignataro 
has demonstrated that among the three NCX brain isoforms, NCX1 and NCX3 
represent two molecular effectors involved in the neuroprotective mechanisms of 
ischemic preconditioning. So, results of Pignataro work support the importance of 
NCX1 and NCX3 in the pathogenesis of ischemic lesion and, most important, offer a 
new possible interpretation of the neuroprotective mechanism elicited by ischemic 
preconditioning. Furthermore the overexpression of NCX1 and NCX3 observed 
during preconditioning may be related to their ability to counteract the dysregulation 
of intracellular Na+, ([Na+]I ) and Ca
2+, ([Ca2+]I ) homeostasis occurring in the brain 
under anoxic conditions corresponding to an harmful ischemia. In a rat model of 
cerebral transient ischemia the reduction in NCX1 expression induced by the 
ischemic insult alone (Boscia et al, 2009; Pignataro et al, 2004) was completely 
prevented when the animals were exposed to preconditioning alone. Indeed, since 
NCX1 and NCX3 silencing partially prevented ischemic neuroprotection mediated by 
preconditioning these results have shown that it would be reasonable to tune up a 
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pharmacological strategy able to modulate NCX1. This approach has been derived 
from the evidence that is possible to hypothesize that the increased expression of 
certain proteins induced by a neuroprotective strategy like preconditioning could 
render the brain tissue ready to withstand subsequent, more severe brain conditions. 
Interestingly, the activation of these mechanisms has appeared to be long lasting, as 
relatively to sodium/calcium exchanger protein the upregulation of NCX1 and NCX3 
was still present even after 72 h after preconditioning induction, thus suggesting that 
both NCX1 and NCX3 might be considered as two possible effectors of delayed 
preconditioning. More important, the increased expression of NCX1 and NCX3 
observed at early time points does not necessarily implicated that the 
neuroprotection might have occured at the same time points. The results mentioned 
in this study have suggested that, in order to reduce the extension of the infarct 
volume after a harmful ischemic insult an enhancement of NCX1 and NCX3 
expression and/or activity might be desirable. 
 
2.4.3 MECHANISM OF ACTION OF SODIUM/CALCIUM EXCHANGER 
The NCX family, which exchanges three Na+ ions for one Ca2+ ion or four Na+ ions 
for one Ca2+ ion depending on [Na+]i and [Ca2
+]i (Fujioka et al, 2000; Kang & 
Hilgemann, 2004; Reeves & Hale, 1984) consists of three dominant genes coding for 
the three different isoforms of the exchanger: NCX1 (Nicoll et al, 1990), NCX2 (Li et 
al, 1994), and NCX3 (Nicoll et al, 1996) proteins. These three genes appear to be 
dispersed, since NCX1, NCX2, and NCX3 have been mapped in mouse 
chromosomes 17, 7, and 12, respectively (Nicoll et al, 1996). At the post-
transcriptional level, at least 12 NCX1 and 3 NCX3 proteins are generated through 
alternative splicing of the primary nuclear transcripts. These variants arise from a 
region of the large intracellular f-loop, are encoded by six small exons defined A to F, 
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and are used in different combinations in a tissue-specific manner. To maintain an 
open reading frame, all splice variants must include either exon A or B, which are 
mutually exclusive (Quednau et al, 1997). NCX1 is composed of 938 amino acids in 
the canine heart and has a molecular mass of 120 kDa and contains nine 
transmembrane segments (TMS). NCX1 amino terminus (N-terminal) is located in the 
extracellular space, whereas the carboxyl terminus (C-terminal) is located 
intracellularly. The nine transmembrane segments can be divided into an N-terminal 
hydrophobic domain, composed of the first five TMS (1–5), and into a C-terminal 
hydrophobic domain, composed of the last four TMS (6–9). These two hydrophobic 
domains are important for the binding and the transport of ions. The first (1–5) TMS 
are separated from the last four (6–9) TMS through a large hydrophilic intracellular 
loop of 550 amino acids, named the f-loop (Nicoll et al, 1999). Although the f-loop is 
not implicated in Na+ and Ca2+ translocation, it is responsible for the regulation of 
NCX activity.  
NCX can facilitate both Ca2+ and Na+ flow in a bidirectional way through the plasma 
membrane (Blaustein & Lederer, 1999; Philipson & Nicoll, 2000) with a stoichiometry 
of 3 Na+ ions versus 1 Ca2+ ion. Depending on the intracellular levels of Na+ and 
Ca2+, NCX can operate in the forward mode by extruding one Ca2+ against three 
entering Na+, using the Na+ gradient across the plasma membrane as a source of 
energy  (Annunziato et al, 2004; Blaustein & Lederer, 1999). Alternatively, in the 
reverse mode, NCX can function as Na+ efflux–Ca2+ influx. Because of its high 
exchange capacity, NCX is well-suited for rapid recovery from high intracellular Ca2+ 
concentrations ([Ca2+]i) and may play an important role in maintaining Ca
2+ 
homeostasis and protecting cells from Ca2+ overload and eventual death (Annunziato 
et al, 2004; Blaustein & Lederer, 1999). 
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2.4.4 REGULATION OF SODIUM/CALCIUM EXCHANGER 
During brain ischemia there is a dramatic impairment of mechanisms regulating the 
homeostasis of sodium and calcium ions between the internal neurons and their 
extracellular melieu. One of the crucial actors of these biochemical deleterious 
events leading to neuronal cell pain is represented by the sodium/calcium exchanger 
(conventionally referred to as NCX). The activity of this  membrane antiporter protein 
has been focused for several years of experimental work of our research group. The 
exchanger acts by modulating in excitable cells the intracellular concentrations of Na+ 
and Ca2+ ions, thus providing for the maintenance of cell ions homeostasis. NCX 
mediates ions fluxes of Ca2+ and Na+ ions across the plasma membrane in a 
bidirectional way (Annunziato et al, 2004; Blaustein & Lederer, 1999; Philipson & 
Nicoll, 2000). There are several factors that regulate the activity of the exchanger 
sodium calcium, among which: (i) the concentration of the two cations transported, 
Na+ and Ca2+; (ii) the intracellular pH; (III) compounds related to metabolism, ATP, 
PIP2, PKA and PKC, and (iv) reactive oxygen species (ROS) and reactive nitrogen 
species (RNS). The concentration of calcium regulates NCX through CBD (Ca2+-
binding domain) in the same way the Na+ ion plays a regulatory function. In particular 
when the sodium concentration increases, it binds to the site of transport of the heat 
exchanger, and after this influx of sodium, is an inactivation of the same. This 
process of inactivation, is very similar to the phenomenon that occurs in the voltage-
gated ion channels, and is called sodium-dependent inactivation. The exchanger can 
also be regulated by the intracellular pH. A strong acidity inhibits the activity of NCX 
leaving it under a constant steady state, in fact, reductions in pH value below 0.4, can 
induce an inhibition of NCX than 90%. The ATP, which acts as a donor of phosphate 
groups, can increase the activity of the exchanger in different ways. First, activating 
the G protein-coupled receptors for endogenous and exogenous ligands. As a 
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second, ATP can stimulate the activity of NCX through the pathway involving PKC or 
PKA; each isoform of NCX is presumed to have several phosphorylation sites. 
Finally, another mechanism by which NCX can be activated requires the production 
of lipid PIP2. In fact, this lipid binds the XIP region of the loop "f" eliminating the 
inactivation of NCX, thus stimulating its function. Interestingly, the depletion of ATP 
within the cell act differently on the three isoforms of the exchanger by inactivating 
both NCX1 and NCX2 but not by influencing the activity of NCX3 (Secondo et al, 
2007) . The sodium-calcium exchanger is sensitive to reactive oxygen species, in fact 
by altered redox cell can result increases the activity of NCX (Annunziato et al, 
2004). Among the main factors that regulate the activity of NCX can be considered, 
quite rightly, miRNAs that have already amply demonstrated to fine-tune their target 
genes at the post-transcriptional level. 
 
2.4.5 SODIUM/CALCIUM EXCHANGER ACTIVATOR: NEUROUNINA 
In recent years there has been great interest in the identification of new compounds 
capable of increasing NCX activity to limit the extension of ischemic brain damage 
(Annunziato et al, 2009). Only NCX inhibitors were available including 3-amino-6- 
chloro-5-[(4-chloro-benzyl)amino]-N-[[(2,4-dimethylbenzyl) amino]iminomethyl]-
pyrazinecarboxamide (CB-DMB) (Secondo et al, 2009), KB-R7943 (Watano et al, 
1999), SEA0400 (Matsuda et al, 2001), SM-15811 (Hasegawa et al, 2003) , SN- 6 
(Iwamoto et al, 2004; Iwamoto & Kita, 2006) , and YM-244769  132. These inhibitors 
had a number of interesting features. In particular, KB-R7943 preferentially inhibits 
NCX3 more than NCX1 and NCX2 (Iwamoto et al, 2001), whereas SEA0400 and SN-
6 preferentially block NCX1 rather than NCX2 and NCX3 (Iwamoto et al, 2004; 
Iwamoto & Kita, 2006). However, despite their potency, these compounds possess 
some nonspecific actions against other ion channels and receptors (Pintado et al, 
 
 
37 
 
2000; Reuter et al, 2002). In one of our recent work we developed a potent NCX 
activator, named neurunina. Starting from the structure of one of the most potent 
NCX inhibitors, SM-15811, we synthesized a new compound, 7-nitro-5-phenyl-1- 
(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one. Neurounina  was 
investigated in order to verify the effect on NCX1, NCX2, and NCX3 activity in the 
forward and reverse modes of operation by means of Ca2+ radiotracer, Fura-2 
microfluorimetry, and patch-clamp techniques, and thereafter, with the help of 
chimera strategy, deletion, and site-directed mutagenesis, it were identified the 
molecular determinants of this compound on NCX structure. Neurounina, whose 
structure is illustrated in the inset of figure 4, increases NCX1 and NCX2 activity in a 
concentration-dependent manner but it is not active on NCX3. More important, since 
NCX activity is involved in stroke pathophysiology, it was examined the putative 
protective effects of neurounina on in vitro and in vivo models of cerebral ischemia. 
This compound  provided with an high lipophilicity index and exerted a 
neuroprotective action in an animal model of stroke (tMCAO) (Molinaro et al, 2013) 
(Fig 5).  
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Fig. 4. Effect of neurounina-1 on NCX1, NCX2, and NCX3 activity measured by Na
+
-dependent 
45
Ca
2+
 influx/efflux and Fura-2-monitored Ca
2+
 techniques. Inset shows the chemical structure of 
neurounina-1. (A and B) concentration-response curves of the effects of neurounina-1 on Nao 
dependent 
45
Ca
2+
 efflux and Nao-dependent 
45
Ca
2+
 uptake, respectively, in BHK cells expressing 
NCX1, NCX2, or NCX3. (C) effect of neurounina-1 (0.0001–0.01 µM) on NCX1, NCX2, and NCX3 
activity measured by single-cell Fura-2 AM microfluorimetry (n = 60 cells for each group). (Molinaro et 
al, 2013). 
 
Fig. 5. After stroke onset. Each column represents the mean ± S.E.M. of the percentage of the infarct 
volume compared with the ipsilateral hemisphere. Each dot represents the single value measured. 
*P< 0.05 vs. control group. **P < 0.05 vs. 0.01 mg/kg treated group.(Molinaro et al, 2013) 
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3. AIM OF THE STUDY 
Hypoxic-ischemic encephalopathy (HIE) accounts for the majority of developmental, 
motor and cognitive deﬁcits in children, leading to life-long neurological impairments. 
Since transient brain ischemia followed by reoxygenation alters ionic homeostasis in 
adult brain and the plasma membrane sodium/calcium exchanger (NCX) plays a 
fundamental role in the maintenance of ionic homeostasis during brain ischemia, we 
aim to demonstrate the involvement of NCX in the pathophysiology of HIE. In 
particular the purpose of the present study was (1) to evaluate the protein expression 
profile of NCX1, NCX2 and NCX3 in the brain of mice subjected to neonatal hypoxia 
ischemia till adulthood; (2) to evaluate the effect of NCX activator on the 
development of HIE hippocampal lesion; and (3) to verify whether long term 
behavioral dysfunctions caused by HIE could be prevented by activating NCX (Fig. 
6). 
 
Fig. 6. Neonatal HI leads to behavioral impairment caused in part by development of dysregulation of 
ionic homeostasis HI-induced. 
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4. MATERIAL AND METHODS 
4.1 STUDY DESIGN 
In order to accomplish the proposed objectives, the study has been divided in three 
phases: 
Phase 1. NCX1, NCX2 and NCX3 expression was evaluated in hyppocampus of 
mice subjected to neonatal Hypoxic ischemic injury (Fig. 7). The experimental 
groups were randomized as following: 
Group 1. Naive C57BL mice were sacrified at different time intervals in order to verify 
the physiological hyppocampal expression of NCX1 and NCX3 (E16, p0, p5, p7, p10, 
p14, p21, p28 and p60) and the relative mRNA (p10 and p14) 
Group 2. p7 C57BL mice were subjected to only hypoxia and were sacrified 3 and 7 
days (p10 and p14) after injury in order to verify NCX1 and NCX3 mRNA expression 
Group 3. p7 C57BL mice were subjected to Hypooxia-Ischemia and were sacrified at 
different time intervals after injury (p10, p14, p21, p28 and p60), to verify NCX1, 
NCX2 and NCX3 protein expression and the relative mRNA (p10 and p14) in order to 
compare with physiological levels. 
 
Fig. 7. Phase 1 experimental program 
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Phase 2.  NCX activator, Neuronina, was administered after injury in order to 
verify neuroprotective activity in acute phase of HI injury (Fig. 8). The 
experimental groups were randomized as following:  
Group 1. p7 C57BL mice were subjected to Hypooxia-Ischemia. 2 hours after the 
surgical procedure of Hypoxia/ischemia induction, animals were treated with 100 
µL i.p. of saline solution  
Group 2. p7 C57BL mice were subjected to Hypooxia-Ischemia. 2 hours after the 
surgical procedure of Hypoxia/ischemia induction, animals were treated with 100 
µL of Neurounina saline solution at dose of and 30 mg/kg i.p. 
 
 
Fig. 8. Phase 2 experimental program 
 
 
Phase 3. Neurounina compuond was administered in adult mice 60 days after 
injury, 3-5 hours before behavioral test evaluation in order to verify whether  the 
increased NCX activity was able to ameliorate behavioral deficits induced by 
neonatal hypoxia ischemia (Fig. 9). The experimental groups were randomized as 
following: 
 
Group 1. p7 C57BL mice were subjected to Hypooxia-Ischemia. Around 53 days 
after injury, p60 animals were treated with 100 µL of Neurounina saline solution at 
dose of and 30 mg/kg i.p. 3-5 hours before behvioral tests. 
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Group 2. p7 C57BL mice were subjected to Hypooxia-Ischemia. Around 53 days 
after injury, p60 animals were treated with 100 µL of saline solution with i.p. 
injection 3-5 hours before behvioral tests. 
Group 3. p60 C57BL naive mice were treated with 100 µL of Neurounina saline 
solution at dose of and 30 mg/kg i.p. 3-5 hours before behvioral tests. 
Group 4. p60 C57BL naive mice were treated with 100 µL of saline solution at 
with i.p. injection 3-5 hours before behvioral tests. 
 
 
 
Fig. 9. Phase 3 experimental program 
 
 
4.2 PROPIDIUM IODIDE LABELING, TISSUE PREPARATION AND 
DAMAGE ANALYSIS  
 
Five microliters of propidium iodide (PI, 1 mg/mL in distilled water, Sigma) were 
injected into the right lateral brain ventricle of newborn mice. Twenty minutes after 
injection, pups were deeply anesthetized and perfusion-fixed with 4% 
paraformaldehyde in 0.1 mol/L PBS. Brains were rapidly removed on ice and 
processed for antigen retrieval by immersing overnight in 10 mmol/L sodium citrate 
buffer (pH 6.0, 4 °C) and boiling in the same buffer for 3 min. After boiling, brains 
were cryoprotected with 30% sucrose/PBS (72 h, 4 °C). Preliminary experiments 
have shown that the boiling procedure does not affect the distribution of the dye 
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(Carloni et al, 2007; Unal Cevik & Dalkara, 2003). The brains were cut on a cryostat 
into coronal sections (thickness 20μm) and then processed for immuno-fluoscence 
analyses. In initial experiments, propidium iodide dye has been injected into the right 
lateral ventricle of both control (neither hypoxic nor ischemic; n=3) and sham-
operated hypoxic animals (subjected only to the hypoxic procedure; n=2) and no dye 
detection was found. Sections were analyzed under a microscope (Nikon E400). The 
infarct area PI-stained was calculated comparing it with whole ipsilateral 
hippocampus to determine the percentage of area damaged. The tissue loss instead, 
was calculated comparing the area of ipsilateral and controlateral emisphere. 
 
4.3 IMMUNOHISTOCHEMISTRY 
Immunostaining and confocal immunofluorescence procedures were performed as 
previously described (Boscia et al., 2009). PI-labeled cryosections were incubated 
with 1.5% normal blocking serum for 1 h at room temperature and then incubated 
overnight at 4 °C with the following antibodies: neuron-specific nuclear protein (anti-
NeuN, mouse monoclonal antibody; 1:500; Chemicon); glial fibrillary acidic protein 
(GFAP, rabbit polyclonal antibody; 1:300; DAKO). In other experiment, the 
cryosections were incubated with 1.5% normal blocking serum for 1 h at room 
temperature and then incubated overnight at 4 °C with the following antibodies: 
mouse monoclonal anti-NCX1 (1:500) rabbit polyclonal anti-NCX3 (1:4000), neuron-
specific nuclear protein (anti-NeuN, mouse monoclonal antibody; 1:500; Chemicon). 
Sections processed for NeuN were incubated with the corresponding biotinylated 
secondary antibody, and the peroxidase reaction was developed using 3,3- 
diaminobenzidine/4-HCl as a chromogen. Sections processed for 
immunofluorescence analysis were incubated with the corresponding fluorescent-
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labeled secondary antibodies (Alexa 488/Alexa 594-conjugated anti-mouse/anti-
rabbit IgGs). Images were observed using a Zeiss LSM510 META/laser scanning 
confocal microscope. Single images were taken with an optical thickness of 0.7 m 
and a resolution of 1024 × 1024. In double-labeled sections, the pattern of 
immunoreactivity for both antigens was identical to that seen in single-stained 
material. Controls of the methods in the double immunofluorescence experiments 
included replacement of the primary antisera with normal serum (1:200). To control 
for a possible cross-reactivity between IgGs in double immunolabeling experiments, 
some sections were processed through the same immunocytochemical sequence 
except that primary antisera were replaced with normal serum, or only one primary 
antibody was applied, but the full complement of secondary antibodies was 
maintained. In addition, the secondary antibodies utilized were highly pre-adsorbed 
to the IgGs of numerous species. Tissue labeling without primary antibodies was also 
tested to exclude autofluorescence. No specific staining was observed under these 
control conditions, thus confirming the specificity of the immunosignals. 
 
4.4 MRNA EXPRESSION ANALYSIS BY REAL-TIME POLYMERASE 
CHAIN REACTION 
 
Mice ipsilesional hemispheres belonging to mice underwent only to hypoxia and to 
hypoxic-ischemic insult both 3 and 7 days after surgery were frozen on dry ice. Brain 
samples were ground into powered dry ice, then Trizol Reagent solution (Invitrogen, 
Milan, Italy) was added. Total RNA was extracted and purified in accordance with the 
manufacturer’s protocol. For reverse transcription, 2.0 mg of each extracted RNA 
was digested with DNase and reverse transcribed using iScript cDNA synthesis kit 
(Bio-Rad, Segrate, Milan, Italy). Amplification was performed using Power Sybr 
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Green PCR Master Mix (Applied Biosystem, Milan, Italy) according to the 
manufacturer’s protocol. All data were normalized to hypoxanthine 
phosphoribosyltransferase 1 mRNA levels and expressed as percentage of the 
mRNA levels detected in sham-operated animals. 
Sequences of the primers used were the following: 
NCX1-forward, 5 -CCGTGACTGCCGTTGTGTT-3 ; NCX1-reverse, 5 -
GCCTATAGACGCATCTG-CATACTG-3 ; NCX3-forward, 5 -CCTCTGTGCCA-
GATACATTTGC-3 ; NCX3-reverse, 5 -CC-AAACCAATACCCAGGAAGAC-3 ; 
hypoxanthine-guanine phosphoribosyl transferase (HGPRT)-forward, 5 -
TCCATTCCTATGAC-TGTAGATTTTATCAG-3 ; HGPRT-reverse, 5 -
AACTTTTATGTCCCCCGTTGACT-3.  
4.5 PROTEIN EXPRESSION ANALYSIS 
Whole-cell protein extracts from dissected areas were obtained and processed as 
previously described (Secondo et al, 2007). Nitrocellulose membranes were incu-
bated with anti-NCX1 antibody (rabbit poly-clonal; Swant, Bellinzona, Switzerland; 
1:1000 dilution), anti-NCX2 antibody (rabbit polyclonal; AlphaDiagnostics In-
ternational, San Antonio, TX; 1:1000 dilution), anti-NCX3 antibody (rabbit polyclonal; 
1:2000; kindly provided by K. D. Philipson and D. Nicoll, University of California, Los 
Angeles, CA) and anti- β-tubulin (Sigma-Aldrich rabbit polyclonal 1:1000 dilution). 
These nitrocellulose membranes were first washed with 0.1% Tween 20 and then 
incubated with the corresponding secondary antibodies for 1 h (GE Healthcare, Little 
Chalfont, UK). Immunoreactive bands were detected with the ECL (GE Healthcare). 
The optical density of the bands (normalized with-β tubulin) (Sigma, St. Louis, MO) 
was determined by Chemi-Doc Imaging System (Bio-Rad, Segrate, Italy)  
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4.6 INDUCTION OF NEONATAL HI 
Postnatal day 7 (P7) C57BL6J mice were anesthetized with isofluorane (4% for 
induction, 1% for maintenance), 30% O2, and 70% N2O. The body temperature of the 
animal was maintained at 37C during the whole procedure with a heating pad. Under 
a surgical stereo microscope, a midline skin incision (0.5 cm) was made on the neck, 
and the right common carotid artery was exposed, isolated and electrically 
cauterized. The incision was rinsed with 1% lidocaine and sutured with a 6.0 
polypropylene (Prolene) suture. Animals were returned to their dams and observed 
continuously for 30 min during a recovery period of 1 hour. To induce ipsilateral 
ischemic injury as described by Vannucci et al., the animals were placed into an 
hypoxic chamber, perfused with an equilibrated gaseous mixture made from 8% O2 
and 92% N2 at 37 °C; the chamber was placed in a water bath heated to 37 °C for 60 
minutes. After HI, animals were monitored continuously for 30 min and then checked 
every 30 min for 2 h and then daily until they were sacrificed. 
 
4.7 BEHAVIORAL STUDIES 
At two months of life mice were analyzed in behavioral performance tests. 
Experiments were performed under diurnal lighting conditions between 10:00 A.M. 
and 5:00 P.M. Neurounina-1 saline solution was administered (dose 30 mg/kg i.p) 3-
5 hours before the behavioral test. Exploratory behavior was acquired with a high 
definition digital camera while on-line videotracking of animals was computed using a 
custom software written in Matlab environment. 
  
 
 
47 
 
 
4.7.1 OPEN-FIELD EXPLORATION TEST 
The open field apparatus consisting of a transparent Plexiglas square arena (50x50 
cm, 40 cm high) was placed in a homogenously lit experimental room with several 
large-scale environmental visual cues. Briefly, mice were placed in the arena and 
were allowed to explore it for 5 min. Total traveled distance was measured using an 
automated tracking device. Moreover, the time spent by animals in three concentric 
areas was automatically measured as an index of anxious behavior (Kassed & 
Herkenham, 2004); (Kazlauckas et al, 2005). Since the probability to explore an area 
is proportional to the size of the area, the time spent in each area was also divided by 
the percentage size of the total area to obtain unbiased estimates. At the end of the 
test, the number of fecal boluses was counted to evaluate anxious behavior. The 
same apparatus was also used for the object recognition task. 
4.7.2 ELEVATED ZERO MAZE 
The elevated zero maze is a modification of the elevated plus maze used for 
assessing anxiety-related behaviors. Use of the circular maze removes any ambiguity 
in data interpretation as there is no center zone (Lister, 1990; Rodgers et al, 1997; 
Shepherd et al, 1994). The elevated circular platform (40 cm off the ground, 50 cm in 
diameter) had two enclosed arenas opposite each other (5 cm wide with 15 cm high 
walls) and two open arenas (5 cm wide). At the start of the test, each mouse was 
lowered by its tail into the open arena of the maze and allowed to explore the maze 
for 300 s. Activity of the mouse was monitored via an overhead camera connected to 
a computer in a separate room using video acquisition and ANY-maze analysis 
software (Stoelting, Wood Dale, IL). Data analyzed included percentage of time spent 
in the open versus closed arenas and the total distance traveled in the maze. 
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4.7.3 DELAY-DEPENDENT ONE-TRIAL OBJECT RECOGNITION TASK 
Two different objects that differed in terms of height, color, shape, and surface 
texture were used. Both of them had sufficient weight to ensure that the mice could 
not displace them, had no ethological significance for the mice, and had never been 
paired with a reinforcer. Indeed, pilot studies have ensured that mice of the C57BL/6J 
genetic background strain cannot discriminate between objects and have no 
preference for one object over another (Ennaceur & Delacour, 1988)-(Dere et al, 
2007). Procedure. Mice were subjected to two types of trials: a sample trial and a test 
trial. During the sample trial, which took place 1 d after exposure to the open field so 
as to allow the animals to habituate to the test apparatus, all mice were presented 
with the first pair of identical objects. Briefly, the animal was placed on one side of 
the open field, whereas, on the opposite side, two copies of the same objects were 
placed 10 cm from the two corners. After 10 min, the animal was removed from the 
open field and were returned to their home cage (Ennaceur & Delacour, 1988); (Dere 
et al, 2007). During the trial phase, instead, H/I and WT mice were tested for item 
recognition (10 min) 5 min and 24h after sample trial phase. The animal was again 
released into the open field, now containing two objects: the familiar one used during 
the sample trial and the novel object, which was randomly positioned (Ennaceur & 
Delacour, 1988); (Dere et al, 2007).The time spent by each mouse in exploring the 
two objects was measured using an automated tracking device that record the 
mouse position coordinate and the two objects coordinates to match them. 
Exploration of an object was assumed when the mouse approached an object, when 
touched it with either its vibrissae, snout, or forepaws. The percentage of time spent 
exploring the novel object, compared with the total time spent exploring both objects, 
was recorded and considered as a measure of object recognition: recognition index = 
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t novel / (t novel + t familiar ) X 100. Recognition index values >50 suggest a 
preference for the novel object, values close to 50 suggest no recognition, and 
values well below 50 suggest a preference for the familiar object (Dere et al, 2007; 
Ennaceur & Delacour, 1988; Kassed & Herkenham, 2004; Kazlauckas et al, 2005). 
4.7.4 BARNES CIRCULAR MAZE TASK 
The behavioral apparatus used in this experiment consisted of a white circular 
platform (1.22 m diameter) elevated 40 cm above the floor, with 36 equally spaced 
holes (each 5 cm diameter) around the periphery (5 cm from the perimeter). Only one 
hole led to a dark escape box (5cm X5cm X11cm) that was fixed in relation to the 
distal environmental cues and contained some dust-free sawdust bedding which was 
changed between trials. The platform surface was randomly rotated from trial to trial 
to prevent the use of local olfactory, visual, or tactile cues and was brightly 
illuminated from above. The illumination served as motivation to escape in the dark 
box (Bach et al, 1995); (Seeger et al, 2004). During procedure mice were gently 
picked up from the tail and placed in the middle of the platform. The direction faced 
by the animals at the start position was random and changed from trial to trial. After 5 
min, if the mice did not find the goal they were gently directed toward the correct 
hole, and allowed to descend into the escape box where they were left for 1min 
(Bach et al, 1995); (Seeger et al, 2004).On the following 5 d, test trials (one trial per 
day) were performed under identical conditions. Each trial ended when the mouse 
entered the goal tunnel or after a maximum time of 5 min. The amount of time it took 
the mice to enter the escape hole (escape latency) was recorded (Bach et al, 1995); 
(Seeger et al, 2004). 
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4.7.5 T-MAZE SPONTANEOUS ALTERNATION 
This procedure was carried out in an enclosed “T” shaped maze (Med Associated, 
St. Albans, VT) in which long arm of the T (47 cm × 10 cm) serves as a start arm and 
the short arms of the T (35 cm × 10 cm) serve as the goal arms. In this task the 
mouse was placed in the start arm and after 5 seconds the door was opened and the 
mouse was allowed to choose and explore one of the goal arms. When the mouse 
had fully entered the choice arm (tail tip all the way in) a guillotine door was closed 
and the mouse was confined to the choice arm for 30 s. The mouse was then 
removed, the guillotine door lifted and the next trial initiated. This was repeated for a 
total of 9 trials. If the mouse did not make a choice within 2 min the trial was ended 
and advanced to the next. At the conclusion of each trial the maze was cleaned of 
urine and feces. 
 
4.8 STATISTICAL ANALYSIS 
The data were evaluated as means ± SEM. Statistically significant differences among 
means were determined by ANOVA followed by Student-Newman-Keuls test. The 
threshold for statistical significance data was set at P < 0.05. The non-parametric 
data related to some behavioral test, were analyzed using the non-parametric 
Kruskal-Wallis test, followed by the Nemenyi test for the non-parametric multiple 
comparison Statistical significance was accepted at the 95% confidence level 
(p<0.05). 
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5. RESULTS 
 
5.1 HIE DETERMINES A LOSS OF HYPPOCAMPAL PYRAMIDAL 
NEURONS THAT PEAKS 72 HOURS AFTER INJURY INDUCTION 
 
Hippocampal injury was detectable in the ipsilateral hemisphere of HI mice, as 
reflected by hippocampal atrophy. PI–positive cells were detected in the ipsilateral 
hippocampus in CA1, CA2, and CA3 regions as confirmed by immunohistochemical 
analysis (Fig. 10), the PI-stained area was compared with whole ipsilateral 
hippocampus to determine the percentage of damage 24h, 48h, 72h and 7d after 
injury. The biggest damage area was obtained 72h after insult (Fig. 11). 53 days after 
injury (p60 mice), there were not PI stained cells but the number of neurons was 
significantly reduced reaching a value close to 40% (Fig. 12). 
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A.  
 
 
B.  
 
 
Fig. 10. Characterization of damage in the 
ipsilateral hippocampus 3 days after HI injury. 
(A) Stereotactic coordinate of damage relative 
to bregma. (B) Immunofluorescence staining in 
the CA1: Neun (green) and PI (red). The 
pyramidal neurons seem to be affected by the 
injury. (C) Immunofluorescence staining in the 
CA1: GFAP (green) and PI (red) shows the 
ongoing gliosis after injury. 
C.  
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Fig. 11. PI-stained area was compared with whole ipsilateral hippocampus to determine the 
percentage of damage 24h, 48h, 72h and 7d after injury. There is a peak of damage around 72h after 
injury. 
 
 
A. 
 
 
B. 
 
Fig. 12. In p60 mice (53 days after injury) there were not PI stained cells but the number of neurons in 
CA1 CA2 and CA3 was reduced about 40%. (A) Counting of hippocampal neuronal cells. (B) 
Immunofluorescence staining of hippocampus of control and HI mice (Neun green). 
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5.2 ACTIVATION OF NCX WITH NEUROUNINA REDUCES NEURONAL 
INJURY IN HIPPOCAMPUS 
 
To investigate whether NCX activity plays a role in neuronal injury after HI, the effect 
of the potent NCX activator Neurounina on H/I related brain injury was examined. 
Brain damage was assessed with Propidium Iodide technique, a method that detects 
degenerative cells (Carloni et al, 2007; Unal Cevik & Dalkara, 2003) . As shown in 
figure 13. , hippocampal injury was visible in the ipsilateral hemisphere of HI vehicle 
treated animals, as reflected by hippocampal atrophy. 72h after injury, PI–positive 
cells were detected in the ipsilateral hippocampus in CA1, CA2, and CA3 regions. In 
contrast, in the animals Neurounina treated after injury, the ipsilateral hippocampus 
exhibited smaller lesions, reflected by better preserved hippocampal morphology 
(Fig. 13) and fewer PI–positive cells in the pyramidal neuronal layers of CA1, CA2, 
and CA3. In the vehicle treatment animals, PI–positive cells appeared in ipsilateral 
hippocampus and sometime in striatum, thalamus, and some cerebral cortical areas. 
The animals treated with neurounina after HI induction exhibited neuroprotection in 
these brain regions, with no PI–positive cells visible in the ipsilateral striatum and 
thalamus, and fewer PI–positive cells were found in pyramidal neuronal layers of 
CA1, CA2 and CA3. Moreover comparing controlateral and ipsilateral emisphere it 
was evaluated the significant reduction of tissue loss in the Neurounina treated 
animals when compared to vehicle treated animals. These data clearly highlighted 
the neuroprotective effects of increasing NCX activity with Neurounina after hypoxia-
ischemia in acute phase. 
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5.2.1 QUANTITATIVE ANALYSIS OF NEUROPROTECTION MEDIATED BY NEUROUNINA  
As shown in figure 13, background, a nonspecific signal of PI staining was detected 
in the contralateral hippocampus of brain at 72 h after HI. In contrast, the ipsilateral 
hippocampus exhibited a higher level of specific PI fluorescence signals in CA1, 
CA2, CA3, and DG regions. The animals neurounina treated showed at the brain 
level fewer PI–positive cells (Fig. 13) and a better tissue preservation compared with 
control animals. The hippocampal injury was quantified by measuring the percentage 
of area damaged in the vehicle control and in the animals treated with neurounina. 
Based on the percentage of PI-positive (Fig. 14), neurounina treatment group 
exhibited statistically significant reductions of PI–positive area in the ipsilateral CA1, 
CA2 and CA3 regions of the hippocampus (p<0.05). Moreover the percentage of 
tissue loss in the group of HI mice treated with neurounina, calculated comparing the 
ipsilateral hemisphere area with contralateral hemisphere area, was significantly 
decreased if compared to H/I miche treated with vehicle (Fig. 14B). 
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A. B. 
 
 
 
 
 
Fig. 14. Quantitative analysis of neuroprotection mediated by Neurounina. (A) PI-stained area was 
compared with whole ipsilateral hippocampus to determine the percentage of damage (P<0.05). (B) 
the percentage of tissue loss was calculated comparing the ipsilateral hemisphere area with 
contralateral hemisphere area in both experimental groups (P<0.05). 
 
 
 
A. B. 
  
Fig. 13.  Neurounina animals treated after injury, exhibited smaller lesions, reflected by better 
preserved hippocampal morphology and fewer PI–positive cells in the pyramidal neuronal layers of 
CA1, CA2, and CA3. (A) Vehicle treated animal (B)  Neurounina treated animal 
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5.3 NCX1, NCX2 AND NCX3 EVALUATION AFTER NEONATAL 
HYPOXIA ISCHEMIA 
5.3.1 NCX1, NCX2 AND NCX3 MRNA EXPRESSION IS REDUCED BY NEONATAL HI  
To assess NCX1 and NCX3 mRNA after hypoxia ischemia, a real-time polymerase 
chain reaction was performed 3 and 7 days after injury in the ipsilateral hemisphere 
in the three experimental groups: Naive, only hypoxia and Hypoxia-ischemia mice. 
Three days after hypoxia-ischemia NCX1 and NCX3 mRNA expression was 
significantly reduced than control mice but with no difference compared to only 
hypoxia mice (Fig 15A). Seven days after injury NCX1 and NCX3 mRNA levels were 
reduced to almost 50% compared to only hypoxia mice that recovered the 
physiological levels (Fig. 15B). 
A.  
B.  
Fig. 15. NCX1 and NCX3 mRNA in the ipsilateral hemisphere after hypoxia or hypoxia-ischemia. (A) 3 
days after injury NCX1 and NCX3 mRNAs were significantly reduced only hypoxia and Hypoxia-
ischemia groups compared to naive mice. (B) 7 days after injury NCX1 and NCX3 mRNA levels were 
reduced to almost 50% compared to only hypoxia mice that recovered the physiological levels. 
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5.3.2 NCX1 AND NCX3 PROTEIN EXPRESSION IS REDUCED IN THE HIPPOCAMPUS OF 
INJURED MICE 
 
The expression of NCX-1 and NCX-3 proteins was evaluated by Western Blot 
analysis. A developmental-dependent elevation of NCX-1 and NCX-3 expression was 
noted in immature hippocampus. A low level of the two proteins was detected in E16-
p0 hippocampus and increased in the P5-P21 hippocampus. P21-P60 hippocampus 
exhibited a sustained level of NCX-1 and NCX-3 expression. The β-tubulin III protein 
loading controls were similar among these samples (Fig. 16 A). To assess the role 
played by the three different NCX proteins in the H/I mice, NCX-1 and NCX-3 
expression was evaluated in the ipsilateral hippocampus of mice subjected to 
Neonatal Hypoxia-Ischemia at different time points: 1, 3, 7, 14, 21 and 60 days after 
injury and compared with the expression of the two proteins in the same brain region 
of naïve mice (Fig. 16 B-C-; 17 B-C). NCX1 and NCX3 expression was significantly 
reduced from 7 days until 60 days after the Hypoxic-ischemic insult (Fig. 16 B-C-; 17 
B-C). These data were confirmed with immunohistochemical analysis in 7 days after 
injury mice, compared with control mice (Fig. 18-19). By contrast, NCX2 expression 
did not show any change in the two experimental groups (naïve and H/I mice) 7 and 
60 days after injury (Fig. 20). 
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A.  
 
 
B.  
 
 
C.  
 
Fig. 16.(A) NCX1 protein increases in an age dependent manner in brain hippocampus of c57 naive 
mice. (B-C) NCX1 protein expression in hippocampus of mice subjected to hypoxic ischemic injury 
was reduced and did not recover the physiological expression level at all time point considered.  
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A.  
 
   
B.  
 
 
C.  
 
Fig. 17. (A) NCX3 protein increases in an age dependent manner in brain hippocampus of c57 
naive mice. (B-C) NCX3 protein expression in hippocampus of mice subjected to hypoxic 
ischemic injury was reduced and did not recover the physiological expression level at all time 
point considered. 
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Fig. 18. Immunofluorescence staining 7 days after injury. NCX1 expression in hippocampal pyramidal 
neurons is reduced in hypoxic ischemic mice. Neun (green) NCX1 (red) 
 
Fig. 19. Immunofluorescence staining 7 days after injury. NCX3 expression in hippocampal pyramidal 
neurons is reduced in hypoxic ischemic mice. Neun (green) NCX3 (red) 
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A.  
 
B.  
 
 
 
 
 
Fig. 20. NCX2 protein expression in hippocampus of naive injured mice, (A) 7 days after insult (p14) and (B) 53 
days after insult (p60). 
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5.4 NEUROUNINA ADMINISTRATION REVERTS MEMORY DEFICIT IN 
HI MICE 60 DAYS AFTER INJURY 
 
5.4.1 NEUROUNINA PREVENTS ASYMMETRIC BEHAVIOR INDUCED IN MICE BY HI 
Spontaneous alternation is expressed as a percentage and refers to ratio of arm 
choices differing from the previous choice to the total number of arm entries. 
Alternation is used like proof of short term memory deficit. HI mice alternated 
between the arms of the maze less than control mice significantly (P< 0.05), 
supporting the hypothesis of a deficit of working memory (Fig. 21B). HI mice treated 
3-5h before the test with neurounina showed improved outcomes rather than HI mice 
vehicle treated (P> 0.05) and in the same time they did not show any significant 
difference with control groups. This result could be altered by an asymmetric 
development of brain so we looked at the different arms choices of the mice and we 
discovered that HI mice, injured in right emisphere, preferentially choose the right 
arm, this particular result it could be referred to brain asimmetry but it is not evident in 
the mice treated with Neurunina (Fig 21C). 
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A.  
 
B.  
 
C.  
                        
Fig. 21. (A) Apparatus overview. (B) HI mice alternated between the arms of the maze less than 
control mice significantly (P< 0.05), supporting the hypothesis of a deficit of working memory (Fig.). HI 
mice Neurounina treated show improved outcomes rather than HI mice vehicle treated (P> 0.05) and 
in the same time they did not show any significant difference with control groups. (C) HI mice vehicle 
treated preferentially choose the right arm (P<0.05) rather than left one, this particular result it could 
be referred to brain asimmetry 
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5.4.2 HI MICE TREATED WITH NEUROUNINA IMPROVED PERFORMANCE IN ONE-TRIAL 
OBJECT RECOGNITION TASK 
 
H/I mice 8 weeks old did not differ significantly from naive animals in overall health 
and appearance, body weight, and core body temperature. Moreover, no apparent 
alterations in the spontaneous behavior of HI mice were evident in the home cage. 
To examine spontaneous locomotor activity and response to a novel environment, 
we randomized the mice in four groups: naïve mice treated with vehicle, naïve mice 
treated with neurounina, H/I mice treated with vehicle, H/I mice treated with 
neurounina. Mice were assayed in an open field cage with the objects. The amount 
of time spent with the novel object compared with the total time spent exploring both 
objects represents an index of short and long-term memory. During training, animals 
showed no preference for one object over another and there was no difference 
between four animals groups in the exploration time, suggesting that the 
experimental groups were on average equally motivated to explore objects (Fig. 22 
B). However, when presented with a novel object, naïve mice treated with vehicle, 
naïve mice treated with neurounina, but also H/I mice treated with neurounina 
showed a preference for the new one after 10 minutes or 24 h of retention. In 
contrast, H/I mice treated with vehicle group showed a significant lower preference 
for novel objects when compared with other animal groups (Fig. 22 C-D). 
 
 
 
 
 
 
 
66 
 
A.  
 
B.  
 
C.  
 
D.  
 
Fig. 22. Percentage of preference in the training phase between two equal objects (B). Percentage of 
preference in the trial phase of the novel object recognition test 10 minutes (C) and 24 h after the 
training phase (D). 
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5.4.3 HI MICE TREATED WITH NEUROUNINA SHOWED BETTER PERFORMANCE INTO 
BARNES CIRCULAR MAZE TASK  
 
The learning and memory performance of four groups of animals was also evaluated 
by means of the Barnes circular maze test, an hippocampus-dependent cognitive 
task that requires spatial reference memory (Bach et al, 1995; Barnes, 1979; Barnes, 
1988). naïve mice treated with vehicle, naïve mice treated with neurounina, but also 
H/I mice treated with neurounina after the second day showed a significant reduction 
in the escape latency which progressively decreased until the fifth day (Fig. 23 A). In 
contrast, H/I mice treated with vehicle did not show any significant changes in escape 
latencies after the third day and until the fifth day. These escape latencies values 
were significantly higher from 2nd to 5th days H/I mice treated with vehicle group than 
those observed in the other three groups (Fig. 23 A). These results showed that H/I 
mice treated with vehicle did not learn to locate the escape hole during the period of 
observation (days 1–5), thus suggesting an impairment of the spatial learning and 
memory performance that is not evident in H/I mice treated with neurounina.  
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A.  
 
 
Fig. 23. (A) Animals of all four groups were test daily. 
Day 1 the trial was repeated 5 minutes after training 
as proof of working. (B) Barnes apparatus.  
 
B.  
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5.4.4 NEUROUNINA REVERTS THE DISINHIBITED BEHAVIOR OF HI MICE IN OPEN FIELD 
MAZE  
 
Mice examined in an open field test, in order to study whether the reduction of NCX 
affected anxiety related behavior. So the time and the distance spent by animals in 
the center of the arena was compared with that spent in the region close to the walls. 
As this time is related to the size of the central region considered, we evaluated the 
exploration time in central region having a perimeter equivalent to 1/3 of the original 
arena (Fig. 24 A). The time spent in the central area by HI mice treated with vehicle 
differs significantly from the time spent by the other three animal groups considered, 
showing a disinhibited behavior profile (Fig. 24 B-C). There were no significant 
difference in the experimental groups for their locomotor and exploratory behavior 
(Fig. 24 D).  Moreover, the defecation score was not significantly different between 
the four groups (data not shown). 
  
 
 
70 
 
A.  
 
B.  
 
C.  
 
D.  
 
 
Fig. 24. Locomotor activity and anxiety 
levels. Time spent and distance traveled was 
measured using an automated tracking 
device. (A) images of the used apparatus (B) 
Quantification of the time spent by animals in 
the central area as anxious behavior test. 
The time spent in the central area by H/I 
mice treated with vehicle differs 
significantly from the time spent by the 
other three animal groups considered, 
showing a disinhibited behavior profile. 
(C) distance travalled in the central area H/I 
mice treated with vehicle traveled more 
in the central area than other three 
animal groups. (D) Locomotor activity of the  
experimental groups in the open field test. 
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5.5.5 NEUROUNINA REVERTS THE DISINHIBITED BEHAVIOR OF HI MICE IN ELEVATED ZERO 
MAZE 
 
In order to verify whether the reduction of NCX affected anxiety related behavior and 
if the results obtained in the open field were confirmed the animals were assayed in 
zero maze test. The time spent by animals in the open arms was recorded and 
compared in the experimental groups. H/I mice treated with vehicle spent 50% of 
time more than control mice treated with vehicle in the open arms, confirming a 
disinhibited behavior of H/I mice. H/I mice treated with Neurounina showed no 
significant difference when compared with control mice treated with Neurounina (data 
not shown). 
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6. DISCUSSION 
The results of the present study clearly demonstrated for the first time the 
neuroprotective role of Na+ /Ca2+ exchanger NCX in neuronal disfunction following 
neonatal hypoxic ischemic injury.  
The neuroprotective role of NCX has been demonstrated in our and other 
laboratories and several study showed that NCX activation is desirable in several 
pathological disorders such as Alzheimer (Pannaccione et al, 2012; Sokolow et al, 
2011), multiple sclerosis (Kurnellas et al, 2007) and stroke (Molinaro et al, 2008; 
Pignataro et al, 2004). However, although several studies showed the occurrence of 
cellular ionic imbalance during neonatal HI (Friedman & Haddad, 1993; Nabetani et 
al, 1997; Vannucci et al, 2001), nobody investigated the role of NCX in this 
pathology. Therefore, starting from our studies in adult animals, we hypothesized that 
the two NCX brain isoforms, NCX1 and NCX3, could be involved in the pathogenesis 
of ischemic lesion also after neonatal HI. Indeed, we have previously demonstrated 
that in homozygous ncx3−/− mice subjected to MCAO, an increased brain damage 
occurs (Molinaro et al, 2008). In addition, the silencing of NCX1 and NCX3 
expression by RNA interference increases cerebellar granule neurons vulnerability to 
Ca2+ overload and excitotoxicity (Bano et al, 2005; Secondo et al, 2007). Moreover, 
the vulnerability to chemical hypoxia of baby hamster kidney (BHK) cells 
overexpressing NCX1 or NCX3 considerably increases when either NCX1 or NCX3 is 
silenced (Secondo et al, 2007). Further, ischemic rats treated with NCX1 or NCX3 
antisense display a remarkable enlargement of the infarct volume (Pignataro et al, 
2004). In addition, it has been recently shown that among the three NCX brain 
isoforms, NCX1 and NCX3 represent new molecular effectors involved in the 
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neuroprotective mechanisms elicited by “ischemic preconditioning” and "ischemic 
postconditioning" (Pignataro et al, 2012; Pignataro et al, 2013; Pignataro et al, 2011).  
More recently, we demonstrated that a newly synthesized compound, neurounoina, 
by activating NCX in the brain, exerts a remarkable neuroprotective effect in mice 
subjected to tMCAO (Molinaro et al, 2013). Indeed, it was demonstrated that 
neurounina displays a potent and reversible stimulatory effect on NCX1 and NCX2 in 
both forward and reverse modes of operation, with an estimated EC50 in the low 
nanomolar range. Neurounina exerted a remarkable neuroprotective effect in both in 
vitro and in vivo experimental models of cerebral ischemia (Molinaro et al, 2013), 
possibly by enhancing NCX activity. In particular, cortical neurons exposed to 
neurounina displayed a higher resistance to neuronal damage induced by 3 hours of 
OGD or 3 hours of OGD followed by 21 hours of reoxygenation as compared with 
vehicle-treated neurons. It is noteworthy that the results obtained in vivo showed that 
the intraperitoneal administration of neurounina in single doses ranging from 0.003 to 
30 mg/kg significantly reduced infarct volume. 
Our results clearly show that a remarkable neuroprotective effect could be achieved 
also in a model of neonatal hypoxia ischemia. Indeed, neurounina, intraperitoneally 
administered 2 hours after ischemia induction, determines smaller lesions in the 
ipsilateral hippocampus of mice subjected to HI compared to vehicle treated animals, 
this was reflected by better preserved hippocampal morphology and a reduced tissue 
loss. Since neurounina does not affect NCX3, the neuroprotection seen in our model 
has to be ascribed only to NCX1. A possible explanation of this effect resides in the 
fact that neonatal hypoxia–ischemia, although in some aspects different from adult 
ischemia, sets in motion a cascade of metabolic events which culminate in brain 
damage. The role of calcium (Ca2+) as a trigger for irreversible cell injury in hypoxia–
ischemia has been the subject of wide investigation (Farber, 1981; Hossmann et al, 
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1983; Siesjo, 1981). During and following hypoxia–ischemia, altered ion homeostasis 
and membrane depolarization lead to a voltage-dependent influx of Ca2+ ions into 
cells. Additional influx occurs as a consequence of activation of glutamate receptor, 
Ca2+ ion channels and, more importantly, of NCX in the reverse mode. An increase in 
cytosolic Ca2+, in turn, causes phospholipase activation with the accumulation of free 
fatty acids, futile cycling of ions across mitochondria, and subsequent uncoupling of 
oxidative phosphorylation, among other metabolic perturbations investigation 
(Raichle, 1983). 
The onset and magnitude of the calcium increase depend on multiple inherent and 
environmental factors, including the duration (short vs. long) and severity (mild vs. 
severe) of insult, the age of animals (young vs. old), the region of the brain 
(hippocampus, cortex vs. other regions such as thalamus, striatum, dorsal vagal 
neurons, locus coeruleus, cerebellar granule cells), and even the type of cells 
(neurons vs. glial cells). For example, there is a minor or moderate increase in 
cytosolic Ca2+ (decades to hundreds nanomolar) with short or transient 
hypoxia/ischemia, but a large sustained increase in [Ca2+]i (up to 35µM)  in severe 
and prolonged hypoxia/ischemia (Chen et al, 1999; Diarra et al, 1999; Martinez-
Sanchez et al, 2004; Nakamura et al, 1999; Silver et al, 1997; Silver & Erecinska, 
1990; Tymianski et al, 1993; Uematsu et al, 1988; Zhang & Lipton, 1999).  
In addition, it is well known that young animals show a much less extension and 
longer latency (up to ﬁve times longer) of Ca2+ rise in neurons than those of the 
mature ones during hypoxia/ischemia (Friedman & Haddad, 1993; Nabetani et al, 
1997; Vannucci et al, 2001). This could further justify long term protection effect of 
neurounina and, more in general, of other potential NCX activator in this pathology. 
Another interesting aspect that has to be underlined, is the involvment of NCX in the 
long term effect of neonatal HI, in fact it is well known that also in absence of obvious 
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neurologic deficits in the newborn period, long-term functional impairments may be 
present. In the current study, we speculate that NCX activity is reduced at 
hyppocampal level after HI as a result of protein downregulation occurring in adult 
mice previously subjected to neonatal HI. In fact, the impairment of intracellular Na+, 
([Na+]I ) and Ca2+, ([Ca2+]I ) homeostasis persists in adulthood, because NCX1 and 
NCX3 protein expression in hippocampus of mice subjected to neonatal HI was 
drastically reduced starting seven days after injury. Notably, the expression levels of 
these two proteins were not restored anymore after an HI insult, thus causing a 
permanent impairment of ionic homeostasis in the HI hippocampus mice. Therefore, 
we tested neurounina in adult mice (8 weeks of age) that were injured in neonatal 
period, in order to demonstrate that impairment of ionic homeostasis could be one of 
the reason of behavioral disabilities. With this treatment we tried to balance the 
reduced expression of NCX1 with this NCX activator. The results obtained with 
neurounina confirmed the protective effect also in this condition. In fact, HI vehicle 
treated mice showed deficit in working memory; this impairment was reverted by 
treating these mice with neurounina. Similar results were obtained in  tests examining 
spatial, learning and long term memory. Indeed, all these processes were impaired in 
HI mice and were reverted by treatment with neurounina. 
Few researchers have addressed the issue of behavioral problems in children with a 
history of neonatal HIE. In some of these behavioral studies, hyperactivity was 
noticed and was more often present in children with moderate neonatal HIE, but not 
in children with mild neonatal HIE (Marlow et al, 2005; Moster et al, 2002; Robertson 
& Finer, 1988). In addition, one study that used parent’s observations of their child’s 
behavior found more problems related to tractability, aggression, passivity and 
anxiety in a mixed group of children with HIE compared to a control group (Moster, 
Lie et al. 2002). In our experiments we found a situation more similar to that of 
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children with a moderate neonatal HIE, in fact we found a disinhibited behavior of the 
HI mice in the open field test and zero maze test, in which the animals were not 
afraid by the new environment and in which they showed an hyperactive behavior. 
Interestingly, neurounina was able to revert also this behavior rendering animals 
more similar to healthy mice.  
The significant role of NCX1 and NCX3 in the evolution of the developmental brain 
injury and in spatial learning and memory processes in adult mice injured in the 
neonatal period, emerged from the present study. Overall, the findings of the present 
thesis work represents an important milestone in defining short and long term role of 
NCX in the pathology of neonatal HIE.  
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